Literature DB >> 17505031

Long-term survival following pneumonectomy for non-small cell lung cancer: clinical implications for follow-up care.

Dae Joon Kim1, Jin Gu Lee, Chang Young Lee, In-Kyu Park, Kyung Young Chung.   

Abstract

BACKGROUND: The aim of this study was to determine the risk of overall death in long-term survivors (> 5 years) after pneumonectomy for non-small cell lung cancer (NSCLC), and to establish the optimal follow-up strategy for these patients.
METHODS: We analyzed a single-center experience with 94 long-term survivors who underwent pneumonectomy (group A) for NSCLC between January 1992 and December 2000. Prospective tumor registry data were compared with data for 147 long-term survivors who underwent lobectomy (group B) during the same period.
RESULTS: Clinical characteristics at the time of operation differed between the two groups with more squamous histology, larger tumor size, and more advanced stage in group A compared with group B. During follow-up, late lung cancer relapses were rare in both groups (2.1% vs 1.4%), and second primary malignancies were less frequent in group A (2.1% vs 9.5%, p = 0.032). The overall 10-year survival rate was lower in group A than in group B (67.3% vs 82.8%); however, there was no significant difference in lung cancer-specific survival (93.5% vs 95.1%). Intercurrent disease was the leading cause of death in group A (14 patients, 14.9%), most commonly respiratory failure resulting from community-acquired pneumonia.
CONCLUSION: Late cancer relapse or second primary malignancies were rare in long-term survivors after pneumonectomy, but the overall mortality remained high as a result of intercurrent diseases. Continued surveillance should focus on prevention, early detection and aggressive management of intercurrent disease during follow-up care of these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17505031     DOI: 10.1378/chest.07-0554

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Authors:  Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

2.  Postoperative atrial fibrillation in pneumonectomy for primary lung cancer.

Authors:  Hao Wang; Zhexin Wang; Mengmeng Zhou; Jindong Chen; Feng Yao; Liang Zhao; Ben He
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

3.  Pneumonectomy - permanent injury or still effective method of treatment? Early and long-term results and quality of life after pneumonectomy due to non-small cell lung cancer.

Authors:  Piotr J Skrzypczak; Magdalena Roszak; Mariusz Kasprzyk; Anna Kopczyńska; Piotr Gabryel; Wojciech Dyszkiewicz
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-04-04

4.  Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIA non-small cell lung cancer patients.

Authors:  Bo Jia; Qiwen Zheng; Jianjie Li; Jun Zhao; Meina Wu; Tongtong An; Yuyan Wang; Minglei Zhuo; Xue Yang; Hanxiao Chen; Yujia Chi; Jingjing Wang; Xiaoyu Zhai; Yuling He; Lingdong Kong; Ziping Wang
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 3.005

5.  Propensity-matched Analysis Demonstrates Long-term Risk of Respiratory and Cardiac Mortality After Pneumonectomy Compared With Lobectomy for Lung Cancer.

Authors:  Gregory D Jones; Raul Caso; Kay See Tan; Joseph Dycoco; Prasad S Adusumilli; Manjit S Bains; Robert J Downey; James Huang; James M Isbell; Daniela Molena; Bernard J Park; Gaetano Rocco; Valerie W Rusch; Smita Sihag; David R Jones; Matthew J Bott
Journal:  Ann Surg       Date:  2022-04-01       Impact factor: 13.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.